Answer
Myopathy and rhabdomyolysis have been reported in patients taking abiraterone acetate (Zytiga), with most cases developing within the first six months of treatment and recovering after Zytiga withdrawal.
Sources for this answer
- ZYTIGA 500 mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 12Document updated
Sources checked